Multidisciplinary management of lung cancer;Multimodale therapie des kleinzelligen und nichtkleinzelligen lungenkarzinoms

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 22, 2007, Pages 1221-1224

  Serke, Monika ^a   Kollmeier, J ^a  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

Chemotherapy; Non small cell lung cancert; Radiochemotherapy; Small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMORBIDITY; CREATININE CLEARANCE; DIAGNOSTIC APPROACH ROUTE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; REVIEW; TUMOR GROWTH; CANCER STAGING; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SMALL CELL CARCINOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 34347210308     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979402     Document Type: Review

References (19)

1. Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/ consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? Cancel 2005; 104: 2650-2657
2. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24: 1057-1063
3. Dillmann RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer. N Eng J Med 1990; 323: 940-945
4. Dillmann RO, Herndon J, Seagren et al. Improved survival in stage III non small call lung cancer. J Nat Cancer Inst 1996; 88: 1210-1215
5. ESMO. Minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2005(S116): i28-29
6. Fang D, Zhang D et al. Results of surgical resection of patients with primary lung cancers. Ann Thorac Surg 2001; 72: 1155-1159
7. Furuse K, Fukuoka F, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable non-small cell lung cancer. J Clin Oncol 1999; 17: 2692-2699
8. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non small-cell lung cancer. J Clin Oncol 2004; 22: 3852-3959
9. International Union Against Cancer. Lung tumors. Sobin LH, Wittekind Ch. TNM classification of malignant tumors. New York: Wiley-Liss, 1997: 91-97 (82)
10. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2006; 367: 474
11. Lilienbaum RC, Langenberg P, Dickersin K. Single agent chemotherapy versus combination chemotherapy in patients with advanced NS-CLC. Cancer 1998; 82: 116-126
12. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717
13. Perez CA, Pajak TF, Rubin P et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987; 59: 1874-1881
14. Pfister DG, Johnson DH, Azzoli CG et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline. Update 2003. J Clin Oncol 2004; 22,2: 330-353
15. Schiller JH, Harrington D, Belani CP et al for the Eastern Cooperative Oncology Group. Comparison of 4 chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98
16. Serke M. Review: Pharmakologische Therapie des Lungenkarzinoms. Pneumologie 2006; 60: 493-508
17. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103
18. Shepherd FA, Rodrigues PJ, Tudor C et al NCIC Canada. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 2: 123-132
19. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360